![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: H2AFV |
Gene summary for H2AFV |
![]() |
Gene information | Species | Human | Gene symbol | H2AFV | Gene ID | 94239 |
Gene name | H2A.Z variant histone 2 | |
Gene Alias | H2A.Z-2 | |
Cytomap | 7p13 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q71UI9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
94239 | H2AFV | GSM4909280 | Human | Breast | Precancer | 1.85e-02 | -5.06e-02 | 0.0305 |
94239 | H2AFV | GSM4909281 | Human | Breast | IDC | 8.51e-13 | 4.64e-01 | 0.21 |
94239 | H2AFV | GSM4909282 | Human | Breast | IDC | 2.74e-46 | 8.05e-01 | -0.0288 |
94239 | H2AFV | GSM4909287 | Human | Breast | IDC | 1.12e-12 | 4.61e-01 | 0.2057 |
94239 | H2AFV | GSM4909288 | Human | Breast | IDC | 5.05e-11 | 2.76e-01 | 0.0988 |
94239 | H2AFV | GSM4909290 | Human | Breast | IDC | 1.56e-07 | 4.20e-01 | 0.2096 |
94239 | H2AFV | GSM4909294 | Human | Breast | IDC | 1.28e-08 | 2.40e-01 | 0.2022 |
94239 | H2AFV | GSM4909296 | Human | Breast | IDC | 4.00e-17 | 1.66e-01 | 0.1524 |
94239 | H2AFV | GSM4909297 | Human | Breast | IDC | 5.07e-06 | -8.55e-03 | 0.1517 |
94239 | H2AFV | GSM4909301 | Human | Breast | IDC | 1.90e-02 | 2.06e-01 | 0.1577 |
94239 | H2AFV | GSM4909302 | Human | Breast | IDC | 2.44e-02 | 1.84e-01 | 0.1545 |
94239 | H2AFV | GSM4909304 | Human | Breast | IDC | 4.67e-06 | 3.28e-01 | 0.1636 |
94239 | H2AFV | GSM4909306 | Human | Breast | IDC | 6.01e-07 | 3.30e-01 | 0.1564 |
94239 | H2AFV | GSM4909307 | Human | Breast | IDC | 6.22e-14 | 4.84e-01 | 0.1569 |
94239 | H2AFV | GSM4909308 | Human | Breast | IDC | 5.93e-36 | 7.35e-01 | 0.158 |
94239 | H2AFV | GSM4909309 | Human | Breast | IDC | 1.21e-02 | 1.07e-01 | 0.0483 |
94239 | H2AFV | GSM4909311 | Human | Breast | IDC | 8.52e-30 | -2.13e-01 | 0.1534 |
94239 | H2AFV | GSM4909312 | Human | Breast | IDC | 3.99e-13 | 4.31e-02 | 0.1552 |
94239 | H2AFV | GSM4909313 | Human | Breast | IDC | 9.36e-03 | -1.66e-02 | 0.0391 |
94239 | H2AFV | GSM4909315 | Human | Breast | IDC | 1.21e-19 | 5.44e-01 | 0.21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05322 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
hsa053221 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
H2AFV | SNV | Missense_Mutation | c.296C>A | p.Ser99Tyr | p.S99Y | Q71UI9 | protein_coding | deleterious(0) | possibly_damaging(0.552) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
H2AFV | SNV | Missense_Mutation | rs867152303 | c.95N>A | p.Arg32His | p.R32H | Q71UI9 | protein_coding | tolerated(0.08) | benign(0.005) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
H2AFV | SNV | Missense_Mutation | c.229C>A | p.Leu77Ile | p.L77I | Q71UI9 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-AP-A0L8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
H2AFV | SNV | Missense_Mutation | novel | c.155N>T | p.Ala52Val | p.A52V | Q71UI9 | protein_coding | deleterious(0.03) | possibly_damaging(0.667) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
H2AFV | SNV | Missense_Mutation | c.241N>T | p.Arg81Cys | p.R81C | Q71UI9 | protein_coding | deleterious(0.03) | benign(0.012) | TCGA-BS-A0UA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
H2AFV | SNV | Missense_Mutation | c.296N>A | p.Ser99Tyr | p.S99Y | Q71UI9 | protein_coding | deleterious(0) | possibly_damaging(0.552) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
H2AFV | SNV | Missense_Mutation | novel | c.299N>G | p.Leu100Arg | p.L100R | Q71UI9 | protein_coding | deleterious(0) | probably_damaging(0.937) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
H2AFV | SNV | Missense_Mutation | novel | c.49N>A | p.Ala17Thr | p.A17T | Q71UI9 | protein_coding | deleterious(0.04) | benign(0.22) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
H2AFV | SNV | Missense_Mutation | c.119N>A | p.Arg40His | p.R40H | Q71UI9 | protein_coding | deleterious(0.03) | probably_damaging(0.92) | TCGA-FI-A2EX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD | |
H2AFV | SNV | Missense_Mutation | c.229N>G | p.Leu77Val | p.L77V | Q71UI9 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |